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Amantadine and levodopa in the treatment of 
Parkinson's disease 
Twenty-eight ambulatory patients with Parkinson's disease participated in successive 
double-blind crossover trials of amantadine and levodopa. A comprehensive battery of tests 
was used to evaluate patient preference, neurologic symptom~ and signs, quantitative neurologic 
performance, practical skills used in daily living, and neuropsychological performance. These 
permitted differential assessment of specific areas of function affected. 
Levodopa ameliorated functional disabilities, tremor, and loss of as·sociated movements. It 
also improved grip strength, foot speed, foot coordination, gait, and several skilled activities 
more than did amantadine. The combination of levodopa and amantadine was more effective 
than levodopa alone in the management of total functional disability, tremor, and gait and in 
tests of grip strength, finger coordination, tracking, and tandem gait, as well as in the 
practiced skills of zipping, cutting, and opening a door. One neuropsychologic test-picture 
completion-was also better on the combination. The safety of the combination was affirmed 
and the relative efficacy quantitated. 
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In a previous study, we10 addressed our-
selves to the question of whether amanta-
dine was effective in the treatment of 
Parkinson's disease. By qualitative and 
quantitative criteria, amantadine ( Sym-
metrel) was found to be a safe and ef-
fective agent, with specific improvement 
occurring in tests involving gait, coordina-
tion, strength, and more complex activities 
of daily living. We here report a compari-
son of levodopa, amantadine, and the com-
bination of the two in the therapy of par-
kinsonism, using the same battery of sub-
jective and objective tests of neurologic 
and neuropsychological function as in the 
previous study10 and incorporating an ad-
ditional battery of tracking tests designed 
to measure more complex coordinated 
movements. 
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Patients and methods 
Twenty-eight of the 42 patients partici-
pating in the previous trial remained for 
the 18 month duration of the experiment. 
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The original selection method, the tests 
used, and the principles of test application 
have been described.10 A section of the re-
sults deals with those patients who did not 
complete the trial for one reason or an-
other. At the conclusion of the previous 
trial, each patient was begun on levodopa 
therapy and amantadine was gradually 
withdrawn. The dose of levodopa was 
gradually increased over the following 4 
to 5 months, until the patient reached a 
stable, maximal tolerable dose; that is, the 
dose was increased by 250 to 500 mg. in-
crements once or twice weekly until each 
patient developed nausea or other trouble-
some side effects. When such an effect 
was encountered, the patient was given the 
immediately preceding dose, and we 
waited one week before attempting to in-
crease the dose. The patient was considered 
to have reached his maintenance dose only 
after 3 or more unsuccessful attempts were 
made to exceed the dose which produced 
the troublesome side effect. The only side 
effects we considered acceptable were mild 
nausea and anorexia without weight loss. 
Each patient had been on levodopa therapy 
for at least 6 months and had been on main-
tenance dosage for at least 6 weeks at the 
time of the first test period. After evalua-
tion on levodopa alone, patients were ran-
domly allocated into two treatment groups, 
with the use of a double-blind design. One 
group was given 100 mg. of amantadine 
twice daily and the other a placebo capsule 
of identical taste and appearance twice 
daily. Three weeks later, patients returned 
for evaluation. An interval history was ob-
tained and neurologic function evaluated. 
The amantadine and placebo groups were 
then crossed over. Three weeks later, the 
patients returned for a final evaluation. 
Each patient had been evaluated by his-
tory and test battery 7 times by the comple-
tion of the trial, but only the last 5 evalua-
tions are analyzed in this report. 
Evaluations were made: ( 1) on placebo 
alone, ( 2) on amantadine alone, ( 3) on 
levodopa alone, ( 4) on levodopa plus 
placebo, and ( 5) on levodopa plus 
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Table I. Side effects limiting dosage of 
levodopa 
Average dose 
Side effect (Gm.!day) 
Nausea with vomiting 4.3 
Anorexia and weight 
loss 4 3.4 
Dyskinesias (limb, face, 
or axial) 4 2.1 
Depression 2 3.0 
Increased rigidity and 
akinesia 1 4.5 
Nervousness, itchy 
hands 1 5.0 
Bitter taste, burning 
tongue 1 3.0 
Confusion and paranoia 1 0.5 
Orthostatic hypotension 1 2.0 
Anarthria, dysphagia, 
freezing 1 1.0 
amantadine. Crossovers occurred between 
Examinations 1 and 2 (placebo versus 
amantadine) and between Examinations 
4 and 5 ( levodopa plus placebo versus 
levodopa plus amantadine). Age-matched 
control subjects in good health (predomi-
nantly the husbands and wives of the pa-
tients) were used to establish normal 
values. 7 The patient group consisted of 12 
women and 16 men, with an average age 
of 65.6 years, average disease duration 
of 9.25 years, and average stage of 2.9, 
according to the classification of Hoehn 
and Yahr.3 The average maintenance dose 
of levodopa was 3.58 Gm. per day (50 
mg. per kilogram per day) and, as noted, 
they had been on this maximal tolerable 
maintenance dose for at least 6 weeks when 
first tested for the levodopa effect. 
Results 
Dose-limiting side efjects for levodopa 
treatment. Table I lists side effects and 
doses of levodopa in our 28 patients. Dys-
kinetic and affective complications tended 
to appear at a lower dose than did the 
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Table II. Disability, pulse, and blood pressure 
Parameter Placebo Amantadine 
Walking 2.6 2.0" 
Dressing 2.9 2.6 
Hygiene 3.3 3.lt 
Eating 1.1 0.90t 
Feeding 2.1 1.9 
Speech 2.8 2.3" 
Pulse 80.9 79.4 
Blood pressure 
Systolic 121.1 122.3 
Diastolic 79'.8 78.0 
"P < 0.01. 
fp < 0.05. 
other side effects. Only nausea with actual 
vomiting or significant weight loss was con-
sidered sufficient reason for not increasing 
the dose. The maximal tolerable dose for 
the women ( 45.4 mg. per kilogram per 
day) was considerably lower on the average 
than that for the men ( 54.3 mg. per kilo-
gram per day). All the side effects of leva-
dopa encountered disappeared with re-
duction in dosage. 
Comparisons of treatment groups 
(Tables II to VI). In the second column 
of each table, tests which were significantly 
improved with amantadine are indicated 
by asterisks. In Tables IV to VI, the values 
are expressed in terms of percentage of nor-
mal function. Because of the large number 
of tests involved in the quantitative evalua-
tion of neurologic function ( QENF), only 
those tests which were significantly changed 
at some time during the trial have been 
listed. The third column of each table in-
dicates comparisons of amantadine and 
levodopa. In the last two columns, levodopa 
plus amantadine and levodopa plus placebo 
are compared. 
Amantadine. The results in the 28 pa-
tients who completed the entire trial are 
in agreement with the analysis of all 42 
patients previously reported.10 Seven of 27 
neurologic signs, 4 of 6 disability categories, 
Levodopa + 
Levodopa placebo 
1.8 1.9 
2.4t 2.5 
2.5" 2.8 
0.81 0.88 
1.6 1.5 
2.1 1.9 
81.8 83.0 
125.2 125.4 
79.8 80.2 
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Levodopa + 
amantadine 
1.7 
2.3 
2.7 
0.81 
1.4 
1.7 
83.9 
125.2 
79.9 
15 of 42 quantitative tests of neurologic 
function, and 9 of 19 simulated activities of 
daily living were significantly better on 
amantadine than on placebo. The only 
psychological test which improved was the 
digit symbol substitution test, which in-
volves fine motor coordination. Because 
of the extensive analysis in the previous 
paper, this comparison will not be de-
scribed further here, but it clearly indicates 
superiority of amantadine over placebo. 
Levodopa versus amantadine. The pa-
tients reported greater improvement on 
levodopa than amantadine in functional 
disability in 4 of the 6 categories evaluated 
-dressing, hygiene, feeding, and speech. 
The neurologists judged a significant over-
all improvement of tremor in the upper 
extremities, finger movements of the domi-
nant hand, and associated bodily move-
ments bilaterally. For all the other symp-
toms and signs evaluated, the two drugs 
produced indistinguishable benefits. 
The quantitative tests revealed a more 
striking superiority of levodopa over 
amantadine. Twelve of 42 QENF tests 
showed greater improvement on levodopa, 
including grip strength, foot speed, foot 
coordination, and tandem gait. There was 
also a slight but significant improvement 
in two-point discrimination. Amantadine 
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Table III. Standard neurologic examination 
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Levodopa + Levodopa + 
Test Placebo Amantadine Levodopa placebo amantadine 
Tremor 
Right hand 3.4 2.9" 2.5" 2.1 1.8" 
Left hand 2.1 1.8 1.5" 1.4 1.1 
Right leg 1.1 0.9 0.8 0.8 0.5" 
Left leg 0.8 0.7 0.5 0.5 0.2" 
Rigidity, left arm 1.4 0.9" 0.7 0.7 0.6 
Finger coordination 
Right 2.7 2.4 1.9" 1.8 1.7 
Left 2.5 2.0t 1.6 1.6 1.5 
Bradykinesia 2.3 1.9f 1.6 1.5 1.4 
Weakness, right leg 1.0 0.5" 0.4 0.4 0.4 
Rising 1.6 1.1" 1.0 1.0 1.0 
Posture 2.5 2.0 1.8 1.8 1.6 
Gait 2.0 1.6" 1.5 1.5 1.3" 
Loss of associative movement 
Right 4.2 4.1 3.6" 3.6 3.4 
Left 3.8 3.6 3.lt 3.1 2.9 
Only those tests showing significant change at some time during the trial are listed. 
"P < 0.05. 
fp < 0.01. 
tp < 0.001. 
and levodopa produced indistinguishable 
improvement in hand coordination, rotary 
pursuit, and pencil flipping. Analysis of 
the more complex and skilled activities of 
daily living ( SADL) revealed that in 5 of 
19 there was significantly better perform-
ance on levodopa than on amantadine (use 
of zipper, cutting utensils, fork, safety pin, 
opening an envelope). The two drugs pro-
duced indistinguishable improvement in 
use of a small button, tying a bow, squeez-
ing toothpaste, dialing a telephone, drink-
ing from a glass, and scrubbing the hands. 
If the SADL tests are all combined, leva-
dopa produces an average 23.9 per cent 
improvement over placebo compared to a 
6.4 per cent improvement for amantadine. 
The improvement in these complex prac-
ticed skills is more striking than for the 
more basic abilities tested by the QENF. 
Of the nine neuropsychologic tests, two 
showed significantly better performance on 
levodopa (digit symbol substitution and 
object assembly) than amantadine. Both 
have a motor output. 
Neither drug produced significant im-
provement in cogwheeling, speed of rapid 
alternating movements, speed of foot tap-
ping, leg rigidity, or postural stability with 
the eyes closed. A slight but significant 
decrease in grip strength was noted after 
amantadine, while a similar decrease in 
deltoid strength was noted after levodopa. 
Levodopa plus amantadine. No individ-
ual category of functional disability was 
significantly better on the combination of 
drugs, but all the scores were lower on the 
average. If all the disability scores are 
summed, the combination of levodopa and 
amantadine was significantly better than 
levodopa alone. 
Scores from the standard neurologic 
examination reveal that the combination 
improves arm tremor, leg tremor, and gait 
more than does levodopa alone. Analysis 
of the QENF tests reveals that the combi-
32 Walker et al. Clinical Pharmacology 
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Table IV. Quantitative evaluation of neurologic function 
Test 
Grip strength 
D 
N 
Shoulder strength 
D 
N 
Hand coordination 
D 
N 
Index of performance 
D 
N 
Rotary pursuit ( N ) 
Purdue pegboard 
D 
N 
Pencil flip 
D 
N 
Two-point discrimination 
D 
N 
Foot speed 
D 
N 
Foot coordination 
forward 
D 
N 
Index of performance 
forward 
D 
N 
Foot coordination side 
D 
N 
Index of performance 
side 
D 
N 
Placebo 
60.3 
58.2 
68.4 
67.6 
64.3 
63.6 
60.1 
60.7 
49.6 
46.8 
53.5 
41.6 
46.7 
82.6 
87.5 
58.1 
56.3 
46.6 
49.5 
44.5 
48.7 
48.3 
54.4 
42.4 
47.5 
Per cent of normal function 
I Levodopa + Amantadine Levodopa placebo 
67.7" 
64.3t 
74.7 
69.4 
74.6" 
74.3" 
67.3" 
67.7" 
64.7" 
53.9" 
57.0t 
45.1t 
50.7t 
84.0 
86.1 
64.0 
57.6 
54.3t 
58.6f 
49.4 
52.5 
57.3t 
62.3t 
50.4 
53.4 
74.2° 
70.3f 
65.8t 
60.0" 
73.3 
71.6 
66.1 
66.3 
69.9 
62.7" 
64.1" 
45.8 
53.6 
93.1" 
97.7t 
75.0t 
70.6° 
60.5 
64.5 
57.lf 
62.0" 
64.7 
72.1 
59.5t 
61.9f 
68.3 
64.0 
62.3 
58.9 
73.1 
71.2 
68.6 
65.4 
75.1 
62.0 
66.6 
46.4 
50.8 
92.1 
98.7 
72.6 
67.9 
59.3 
63.7 
56.2 
59.0 
62.3 
69.2 
57.2 
61.0 
Levodopa + 
amantadine 
73.6f 
67.4 
65.3 
61.7 
71.5 
74.9 
68.9 
69.4 
87.9 
65.0 
69.8 
54.7 
57.4 
92.6 
93.0f 
74.6 
73.1t 
66.6t 
70.3 
63.5f 
64.4 
70.6t 
71.9 
61.8" 
66.0" 
Only those tests showing a significant change at some time during the trial are listed. D = dominant; N = non-
dominant. 
0 p < 0.01, 
fp < 0.05. 
tP < 0.001. 
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Table IV. Cont'd 
Test 
Tandem gait 
Supported 
Unsupported 
Foot speed forward ( N) 
Touch toe (D) 
Rest tremor ( D ) 
Critical task score 
Movement time-left to 
right 
Placebo 
53.2 
48.9 
80.1 
79.2 
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Per cent of normal function 
Levodopa + Levodopa + 
Amantadine Levodopa placebo amantadine 
58.3 67.6" 66.3 73.5" 
51.9 63.1t 63.3 66.9 
78.6 83.3t 78.4 82.2 
85.2 92.lt 86.4 97.9 
46.1 40.3 52.5t 
78.0 81.5t 
83.4 86.0t 
Table V. Simulated activities of daily living 
Per cent of normal function 
Levodopa + Levodopa + 
Task Placebo Amantadine Levodopa placebo amantadine 
Shirt 29.4 37.9" 47.4 52.5 56.1 
Button 
Large 46.1 52.2 64.0 63.8 67.4 
Small 42.3 47.0t 58.3 52.2 60.1 
Zipper 48.8 59.4t 83.3t 81.7 88.6f 
Bow 44.1 50.1f 69.5 56.5 64.2t 
Cutting 45.1 48.8f 69.2t 63.2 73.3 
Fork 58.2 64.4 89.5t 91.4 95.9 
Toothpaste 52.0 59.2f 75.3 82.7 78.7 
Dialing 68.1 74.2t 83.2 80.7 77.9 
Safety pin 58.2 63.4 84.6t 75.6 77.4 
Envelope 51.5 54.3 96.0t 87.0 89.2 
Door 56.1 65.9 86.0 88.6 97.7t 
Drinking 77.2 82.7t 95.2 97.3 106.0 
Vocalizing 87.7 92.2 87.7 83.6 81.4 
Scrub 
D 60.2 70.9t 89.5 87.4 94.3 
N 60.8 67.9t 81.1 73.5 81.2 
Glove 
D 50.5 64.4 83.1 80.0 87.3 
N 57.5 59.8 85.8 82.7 91.4 
Average 55.5 61.9 79.4 76.7 81.6 
D = dominant; N = nondominant. 
"P < 0.001. 
fp < 0.05. 
tP < 0.01. 
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Table VI. Neuropsychological tests 
Clinical Pharmacology 
and Therapeutics 
Per cent of normal function 
Test Placebo Amantadine 
Similarities 
Digits 92.6 94.4 
Written 50.7 53.5 
Oral 68.4 65.5 
Digit symbol 49.6 55.0" 
Object association 84.6 78.5 
Picture arrangement 83.3 82.1 
Picture composition 84.4 87.6 
Verbal organization test 88.1 88.8 
Raven IQ 90.4 91.5 
Raven 91.4 92.5 
"P < 0.05. 
fp < 0.01. 
nation is superior to levodopa alone for 
the following: dominant hand-grip strength, 
pencil Hipping, dominant foot-foot coordi-
nation and index of performance, nondomi-
nant foot-foot speed, foot coordination and 
index of performance, and tandem gait, 
supported. Thus, amantadine seems to of-
fer an additional boost in function, espe-
cially in terms of coordination in the hands 
and feet. This was also evident in the timed 
SADL tests, in which the combination was 
superior to levodopa alone for zipping, 
cutting, and opening a door. It is important 
to note that amantadine produced an in-
cremental improvement averaging 4.9 per 
cent in these tests, even after the striking 
improvement by levodopa. 
There was little further effect on neuro-
psychological performance with the addi-
tion of amantadine, only picture comple-
tion being significantly better. However, as 
the trial progressed, gradual improvement 
was noted in several other tests, although 
this was not statistically significant. When 
the combination of levodopa and amanta-
dine was compared to initial placebo scores, 
significant improvement was noted for the 
written symbol digit, digit symbol, object 
assembly, picture completion, the verbal 
organization test, and the Raven progres-
sive matrices. 
Side effects of amantadine with leva-
dopa. No new side effects were reported.10 
Levodopa + Levodopa + 
Levodopa placebo amantadine 
83.0 87.5 90.9 
95.3 96.1 100.0 
57.7 64.0 61.9 
64.6 69.8 67.9 
61.5t 60.5 63.4 
82.0" 88.7 93.5 
87.6 91.7 92.9 
86.4 92.8 96.8" 
92.5 95.6 97.5 
91.0 94.7 94.8 
92.6 94.4 96.6 
One patient had recurrence of ankle edema 
which he had experienced when on aman-
tadine in the earlier phase of the trial, 
and two women noted the return of livedo 
reticularis when amantadine was restarted. 
Deaths. Two deaths occurred during the 
trial. The first patient developed symptoms 
of congestive heart failure during the first 
placebo period and this gradually worsened 
during amantadine and levodopa admin-
istration. Heart failure responded poorly 
to digitalis, diuretics, and the withdrawal 
of all anti-Parkinson medications, and she 
eventually died. The second patient had 
an unreported history of periodic ankle 
swelling and had previously taken digitalis 
and diuretics, though he was not taking 
them on admission to the study. Ankle 
swelling recurred both times when aman-
tadine was given, and following the com-
pletion of the trial he developed orthopnea 
and paroxysmal nocturnal dyspnea. Aman-
tadine was withdrawn and he seemed to 
be improving on digoxin and hydrochloro-
thiazide, when he developed acute urinary 
retention and suddenly died at home. 
Pulmonary embolism was suspected, but 
an autopsy was not permitted. Increased 
ambulation with consequent increased 
strain on the heart may have played a 
role in the precipitation of heart failure 
in this patient, though the relation of heart 
failure to amantadine was not clear in the 
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first patient. Congestive heart failure may 
constitute a relative contraindication to 
amantadine administration. 
Discussion 
Our results indicate a somewhat different 
spectrum of effects of levodopa and aman-
tadine in Parkinson's disease and indicate 
an additive effect when the two are com-
bined. The use of a comprehensive, quali-
tative and quantitative test battery such as 
ours makes it possible to analyze such ef-
fects, as well as to screen for adverse effects 
on neurologic function. 
Earlier trials, 1 • 2 • 4 • 6• s, 9 have yielded con-
flicting results concerning additional bene-
fit from amantadine in patients already 
taking levodopa. Initial reports suggested 
that amantadine had an additive effect, 
but these were criticized on the basis of 
technique.4 Godwin-Austen and associates2 
found no additional effect of amantadine 
in 12 patients who were taking levodopa 
and anticholinergic drugs on a stable regi-
men, but objective tests were not used 
in the evaluation. Hunter and associates4 
used only a short "run-in" period of 17 
to 24 days on levodopa before adding 
amantadine. Though additional improve-
ment was noted, they attributed it to 
accumulated levodopa effect. Millac and 
associates, 5 using an ordinal scoring sys-
tem and a single timed test (walking a 
measured distance), found no incremental 
effect of amantadine. Parkes and associ-
ates6 treated 66 patients for one year, 26 
with amantadine alone and 40 more se-
verely disabled patients with the combina-
tion of amantadine and levodopa. They 
found a rapid and persistent effect of 
amantadine, and recommend its use in 
milder cases of parkinsonism, because of 
the lower incidence and severity of side 
effects. None of the previous trials used 
a double-blind placebo controlled cross-
over program in studying the effects of 
amantadine in patients on a stable dose 
of levodopa. Our use of a large battery 
of tests makes possible the distinction of 
specific areas of function which improve, 
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deteriorate, or are unchanged. Use of a 
total score, based or ordinal grading, may 
blur or distort these distinctions, masking 
important changes in specific functional 
categories. 
Conclusions 
1. Levodopa has been shown to be 
superior to amantadine in the relief of 
functional disability (dressing, hygiene, 
feeding, speech) and improving neurologic 
signs (hand tremor, finger coordination, 
and associated movements) of Parkinson's 
disease. Quantitative neurologic testing 
showed levodopa superior to amantadine 
in grip strength, foot speed, foot coordina-
tion, and tandem gait. The simulated ac-
tivities of daily living which were improved 
more by levodopa than amantadine in-
cluded buttoning a small button, tying a 
bow, squeezing toothpaste, dialing a tele-
phone, drinking from a glass, and scrubbing 
the hands. Greater improvement was also 
noted in two psychomotor tasks. 
2. The combination of levodopa and 
amantadine was better than levodopa alone 
in the relief of the following: qualitative 
tests-total functional disability, tremor of 
arms and legs, gait; quantitative tests-grip 
strength and pencil flipping in the domi-
nant hand, foot speed and foot coordina-
tion, tandem gait; activities of daily living 
tests-zipping, cutting, opening a door; and 
neuropsychological tests-picture comple-
tion. 
3. The safety and efficacy of the com-
bination of the two drugs have again 
been demonstrated. 
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